1. Cancer Biology

Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer

  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti  Is a corresponding author
  1. Johns Hopkins University, United States
  2. Johns Hopkins School of Medicine, United States
  3. Stony Brook University, United States
  4. Howard Hughes Medical Institute, Ludwig Center, United States
https://doi.org/10.7554/eLife.61082
Share this article
Cite this article
  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti
(2021)
Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer
eLife 10:e61082.
https://doi.org/10.7554/eLife.61082
  2. Download BibTeX
  3. Download .RIS

Abstract

Determining the etiologic basis of the mutations that are responsible for cancer is one of the fundamental challenges in modern cancer research. Different mutational processes induce different types of DNA mutations, providing 'mutational signatures' that have led to key insights into cancer etiology. The most widely used signatures for assessing genomic data are based on unsupervised patterns that are then retrospectively correlated with certain features of cancer. We show here that supervised machine-learning techniques can identify signatures, called SuperSigs, that are more predictive than those currently available. Surprisingly, we found that aging yields different SuperSigs in different tissues, and the same is true for environmental exposures. We were able to discover SuperSigs associated with obesity, the most important lifestyle factor contributing to cancer in Western populations.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

The following previously published data sets were used
    1. Weinstein
    (2013) TCGA
    CDG @ https://portal.gdc.cancer.gov/.
    https://portal.gdc.cancer.gov/

Article and author information

Author details

  1. Bahman Afsari

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  2. Albert Kuo

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  3. YiFan Zhang

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  4. Lu Li

    Department of Biostatistics, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  5. Kamel Lahouel

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4339-5749

  6. Ludmila Danilova

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2813-3094

  7. Alexander Favorov

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  8. Thomas A Rosenquist

    Department of Pharmacological Sciences, Stony Brook University, Stony Brook, United States
    Competing interests
    No competing interests declared.

  9. Arthur P Grollman

    Department of Pharmacological Sciences, Department of Medicine, Stony Brook University, Stony Brook, United States
    Competing interests
    No competing interests declared.

  10. Ken W Kinzler

    Howard Hughes Medical Institute, Ludwig Center, Baltimore, United States
    Competing interests
    Ken W Kinzler, K.W.K. is a founder of and hold equity, and serve as consultant to Thrive Earlier Detection and Personal Genome Diagnostics. K.W.K. is on the Board of Directors of Thrive Earlier Detection. K.W.K. is a consultant to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. K.W.K. is a consultant to and hold equity in NeoPhore. The companies named above, as well as other companies, have licensed previously described technologies from Johns Hopkins University. K.W.K is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..

  11. Leslie Cope

    Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University, Baltimore, United States
    Competing interests
    No competing interests declared.

  12. Bert Vogelstein

    Ludwig Center & Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, United States
    Competing interests
    Bert Vogelstein, B.V. is a founder of and hold equity, and serve as consultant to Thrive Earlier Detection and Personal Genome Diagnostics. B.V. is a consultant to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. BV is also a consultant to Nexus, and is a consultant to and hold equity in NeoPhore. The companies named above, as well as other companies, have licensed previously described technologies from Johns Hopkins University. B.V. is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..

  13. Cristian Tomasetti

    Oncology, Johns Hopkins School of Medicine, Baltimore, United States
    For correspondence
    ctomasetti@jhu.edu
    Competing interests
    Cristian Tomasetti, C.T. is a consultant to Bayer and Johnson & Johnson. Thrive Earlier Detection has licensed previously described technologies from Johns Hopkins University. C.T. is an inventor on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper have or may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3277-4804

Funding

The John Templeton Foundation (#61471)

  • Bahman Afsari
  • Albert Kuo
  • YiFan Zhang
  • Lu Li
  • Kamel Lahouel
  • Ludmila Danilova
  • Cristian Tomasetti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Afsari et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,027
    views
  • 437
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bahman Afsari
  2. Albert Kuo
  3. YiFan Zhang
  4. Lu Li
  5. Kamel Lahouel
  6. Ludmila Danilova
  7. Alexander Favorov
  8. Thomas A Rosenquist
  9. Arthur P Grollman
  10. Ken W Kinzler
  11. Leslie Cope
  12. Bert Vogelstein
  13. Cristian Tomasetti
(2021)
Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer
eLife 10:e61082.
https://doi.org/10.7554/eLife.61082

Share this article

https://doi.org/10.7554/eLife.61082

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology

    Luminal epithelial cells integrate variable responses to aging into stereotypical changes that underlie breast cancer susceptibility

    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    2. Chromosomes and Gene Expression

    Telomere length sensitive regulation of interleukin receptor 1 type 1 (IL1R1) by the shelterin protein TRF2 modulates immune signalling in the tumour microenvironment

    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.

    1. Cancer Biology

    Unveiling chemotherapy-induced immune landscape remodeling and metabolic reprogramming in lung adenocarcinoma by scRNA-sequencing

    Yiwei Huang, Gujie Wu ... Cheng Zhan
    Research Article

    Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.